Bioreductive activation of a series of indolequinones by human DT- diaphorase: Structure-activity relationships

Journal of Medicinal Chemistry

Volumn 42, Issue 20, 1999, Pages 4071-4080

  Phillips, Roger M ^c   Naylor, Matthew A ^a   Jaffar, Mohammed ^b   Doughty, Stephen W ^c   Everett, Steven A ^a   Breen, Anthony G ^c   Choudry, Guzanfar A ^c   Stratford, Ian J ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZIRIDINYL 1 METHYL 2 (1H INDOLE 4,7 DIONE)PROP BETA EN ALPHA OL; INDOLEQUINONE DERIVATIVE; MITOMYCIN; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME BINDING; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HYPOXIA; MOLECULAR MODEL; REDUCTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL HYPOXIA; DNA DAMAGE; HUMANS; INDOLEQUINONES; INDOLES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0033533801     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm991063z     Document Type: Article

References (37)

1. Ernster, L. DT-diaphorase, a historical review. Chem. Scripta 1987, 27A, 1-13.
2. Ross, D.; Beall, H. D.; Siegel, D.; Traver, R. D.; Gustafsson, D. L. Enzymology of bioreductive drug activation. Br. J. Cancer 1996, 74 (Suppl. XXVII), S1-S8.
3. Radjendirane, V.; Joseph, P.; Lee, Y. H.; Kimura, S.; KleinSzanto, A. J. P.; Gonzalez, F. J.; Jaiswal, A. K. Disruption of the DT-diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J. Biol. Chem. 1998, 273, 7382-7389.
4. Lind, C.; Hochstein, P.; Ernster, L. DT-diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation. Arch. Biochem. Biophys. 1992, 216, 178-185.
5. Malkinson, A. M.; Siegel, D.; Forrest, G. L.; Gazdar, A. F.; Oie, H. K.; Chan, D. C.; Bunn, P. A.; Mabry, M.; Dykes, D. J.; Harrison, S. D.; Ross, D. Elevated DT-diaphorase activity and messenger RNA content in human nonsmall cell lung carcinoma - relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res. 1994, 52, 4752-4757.
6. Workman, P. Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncol. Res. 1994, 6, 6-8.
7. Robertson, N.; Stratford, I. J.; Houlbrook, S.; Carmichael, J.; Adams, G. E. The sensitivity of human tumour cells to quinone bioreductive drugs - What role for DT-diaphorase? Biochem. Pharmacol. 1992, 44, 409-412.
8. Walton, M. I.; Smith, P. J.; Workman, P. The role of NAD(P)H: Quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indolequinone antitumour agent EO9. Cancer Commun. 1991, 3, 199-206.
9. Beall, H. D.; Mulcahy, R. T.; Siegel, D.; Traver, R. D.; Gibson, N. W.; Ross, D. Metabolism of bioreductive antitumour compounds by purified rat and human DT-diaphorase. Cancer Res. 1994, 54, 3194-3201.
10. Phillips, R. M. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione]prop-β-en- α-ol (EO9) by human DT-diaphorase. Biochem. Pharmacol. 1996, 52, 1711-1718.
11. Fitzsimmons, S. A.; Workman, P.; Grever, M.; Paull, K.; Camalier, R.; Lewis, A. D. Reductase enzyme expression across the national cancer institute tumour cell line panel - Correlation with sensitivity to mitomycin C and EO9. J. Natl. Cancer Inst. 1996, 88, 259-269.
12. Robertson, N.; Haigh, A.; Adams, G. E.; Stratford, I. J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer 1994, 30A, 1013-1019.
13. Plumb, J. A.; Gerritsen, M.; Workman, P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indolequinone EO9. Br. J. Cancer 1994, 70, 1136-1143.
14. Plumb, J. A.; Gerritsen, M.; Milroy, R.; Thomson, P.; Workman, P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumour cell lines. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 295-299.
15. Schellens, J. H. M.; Planting, A. S. T.; van Acker, B. A. C.; Loos, W. J.; de Boer Dennert, M.; van der Berg, M. E. L.; Koier, I.; Krediet, R. T.; Stoter, G.; Verweij, J. Phase I and pharmacologic study of the novel indolequinone bioreductive alkylating cytotoxic drug EO9. J. Natl. Cancer Inst. 1994, 86, 906-912.
16. Dirix, L. Y.; Tonnessen, F.; Cassidy, J.; Epelbaum, E.; Huinink, W. W. T.; Pavlidis, N.; Sorio, R.; Gamucci, T.; Wolff, I.; TeVelde, A.; Lan, J.; Verweij, J. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur. J. Cancer 1996, 32A, 2019-2022.
17. Pavlidis, N.; Hanauske, A. R.; Gamucci, T.; Smyth, J.; Lehnert, M.; TeVelde, A.; Lan, J.; Verweij, J. A randomised phase II study with two schedules of the novel indolequinone EO9 in non small cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG). Ann. Oncol. 1996, 7, 529-531.
18. Phillips, R. M.; Loadman, P. M.; Cronin, B. P. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br. J. Cancer 1998, 77, 2112-2119.
19. Naylor, M. A.; Jaffar, M.; Nolan, J.; Stephens, M. A.; Butler, S.; Patel, K. B.; Everett, S. A.; Adams, G. E.; Stratford, I. J. 2-Cyclopropylindolequinones and their analogues as bioreductively activated antitumour agents: structure activity in vitro and efficacy in vivo. J. Med. Chem. 1997, 40, 2335-2346.
20. Naylor, M. A.; Swann, E.; Everett, S. A.; Jaffar, M.; Nolan, J.; Robertson, N.; Lockyer, S. D.; Patel, K. B.; Dennis M. F.; Stratford, M. R. L.; Wardman, P.; Adams, G. E.; Moody, C. J.; Stratford, I. J. Indolequinone antitumour agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia selective cytotoxicity in vitro. J. Med. Chem. 1998, 41, 2720-2731.
21. Jaffar, M.; Naylor, M. A.; Robertson, N.; Lockyer, S. D.; Phillips, R. M.; Everett, S. A.; Adams, G. E.; Stratford, I. J. 5-Substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en-1-ol (EO9, NSC 383459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro. Anti-Cancer Drug Des. 1998, 13, 105-123.
22. Everett, S. A.; Naylor, M. A.; Nolan, J.; Patel, K. B.; Wardman, P. Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia. Anti-Cancer Drug Des. 1998, 13, 635-653.
23. Speckamp, W. N.; Oostveen, E. A. Indoloquinone compounds. Int. Patent WO87/06227, 1987.
24. Beall, H. D.; Liu, Y.; Siegel, D.; Bolton, E. M.; Gibson, N. W.; Ross, D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in the cytotoxicity and induction of DNA damage by streptonigrin. Biochem. Pharmacol. 1996, 51, 645-652.
25. Beall, H. D.; Winski, S.; Swann, E.; Hudnott, A. R.; Cotterill, A. S.; O'Sullivan, N.; Green, S. J.; Bien, R.; Siegel, D.; Ross, D.; Moody, C. J. Indolequinone antitumour agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:Quinone oxidoreductase, and in vitro cytotoxicity. J. Med. Chem. 1998, 41, 4755-4766.
26. Beall, H. D.; Murphy, A. M.; Siegel, D.; Hargreaves, R. H. J.; Butler, J.; Ross, D. Nicotinamide adenine dinucleotide (phosphate):Quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumour quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol. Pharmacol. 1995, 48, 499-504.
27. Beall, H. D.; Winski, S.; Swann, E.; Hudnott, A. R.; Cotterill, A. S.; O'Sullivan, N.; Green, S. J.; Bien, R.; Siegel, D.; Ross, D.; Moody, C. J. Indolequinone antitumour agents: Correlation between quinone structure, rate of metabolism by recombinant human NQO1 and in vitro cytotoxicity. Bioorg. Med. Chem. Lett. 1998, 8, 545-548.
28. Bailey, S. M.; Sugget, N.; Walton, M. I.; Workman, P. Structure activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indolequinones and aziridinyl benzoquinones. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22, 649-653.
29. Li, R.; Bianchet, M. A.; Talalay, P.; Amzel, L. M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8846-8850.
30. Butler, J.; Spanswick, V. J.; Cummings, J. The autoxidation of the reduced forms of EO9. Free Rad. Res. 1996, 25, 141-148.
31. Siegel, D.; Beall, H. D.; Kasai, M.; Arai, H.; Gibson, N. W.; Ross, D. pH dependent inactivation of DT-diaphorase by Mitomycin C and porforomycin. Mol. Pharmacol. 1993, 44, 1128-1134.
32. Traver, R. D.; Horikoshi, T.; Dannenberg, K. D.; Stadlbauer, T. H. W.; Dannenberg, P. V.; Ross, D.; Gibson, N. W. NAD(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992, 52, 797-802.
33. Sambrook, J.; Fritsch, E. F.; Maniatis, T. Small scale preparations of plasmid DNA. In Molecular Cloning, A laboratory manual, 2nd ed.; Sambrook, J., Fritsch, E. F., Maniatis, T., Eds.; Cold Spring Harbour Press: Cold Spring Harbour, NY 1986; pp 1.25-1.28.
34. Phillips, R. M.; Hulbert, P. B.; Bibby, M. C.; Sleigh, N. R.; Double, J. A. In vitro activity of the novel indolequinone EO9 and the influence of pH on cytotoxicity. Br. J. Cancer 1992, 65, 359-364.
35. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimisation, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
36. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1986, 28, 849-857.
37. Nichols, A.; Sharp, K. A.; Honig, B. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins: Struct. Funct. Genet. 1991, 11, 281-296.